Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Capital Employed (2016 - 2025)

Celldex Therapeutics has reported Return on Capital Employed over the past 15 years, most recently at 0.51% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.51% for Q4 2025, down 25.0% from a year ago — trailing twelve months through Dec 2025 was 0.51% (down 25.0% YoY), and the annual figure for FY2025 was 0.45%, down 12.0%.
  • Return on Capital Employed for Q4 2025 was 0.51% at Celldex Therapeutics, down from 0.41% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CLDX hit a ceiling of 0.03% in Q4 2021 and a floor of 0.51% in Q3 2023.
  • Median Return on Capital Employed over the past 5 years was 0.31% (2025), compared with a mean of 0.29%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -38bps in 2023 and later rose 28bps in 2024.
  • Celldex Therapeutics' Return on Capital Employed stood at 0.03% in 2021, then tumbled by -888bps to 0.34% in 2022, then plummeted by -34bps to 0.45% in 2023, then surged by 44bps to 0.25% in 2024, then tumbled by -100bps to 0.51% in 2025.
  • The last three reported values for Return on Capital Employed were 0.51% (Q4 2025), 0.41% (Q3 2025), and 0.34% (Q2 2025) per Business Quant data.